期刊文献+

TGF-β/Smad信号通路在腹膜纤维化发生、防治中的作用 被引量:10

TGF-β/Smad Signaling Pathway in the Preventing and Controlling of the Peritoneum Fibrosis
下载PDF
导出
摘要 腹膜透析是治疗终末期肾衰竭有效的血液透析方法之一。而腹膜纤维化是腹膜透析患者终止腹膜透析治疗的重要原因之一。转化生长因子β1(TGF-β1)是促进腹膜纤维化的重要因子,在腹膜纤维化形成过程中,TGF-β1主要通过信号蛋白Smad2/3调节基因表达,进而促进细胞外基质的生成,促进纤维化的发生。该文主要就TGF-β/Smad信号通路与腹膜纤维化的关系,针对该通路防治腹膜纤维化进行综述。 Peritoneal dialysis is one of the effective treatments for end-stage renal failure. However,peritoneal fibrosis is an important reason of peritoneal dialysis patients abandoning the long-term peritoneal dialysis. TGF-β1 is the important factor causing peritoneal fibrosis. In the process of peritoneal fibrosis, TGF-β1 plays a role in regulating gene expression mainly through Smad2/3 signal protein ,which promotes the formaion of extracellular matrix, and aggravates the occurrence of fibrosis. Here is to make a review on the relationship between TGF-β/Smad signaling pathway and peritoneal fibrosis, the prevention and treatment of peritoneal fibrosis.
出处 《医学综述》 2013年第7期1173-1175,共3页 Medical Recapitulate
关键词 转化生长因子Β SMAD 腹膜纤维化 防治 Transforming growth factor-β Smad Peritoneal fibrosis Prevention and treatment
  • 相关文献

参考文献35

  • 1Williams JD,Craig KJ,Topley N. Peritoneal dialysis:changes to the structure of the peritoneal membrane and potential for biocompatible solutions[J].Kidney International Supplement,2003,(84):S158-S161.
  • 2Williams JD,Craig KJ,Topley N. Morphologic changes in the peritoneal membrane of patients with renal disease[J].Journal of the American Society of Nephrology,2002,(02):470-479.
  • 3Heimbürger O,Waniewski J,Werynski A. 1Peritoneal transport in CAPD patients with permanent loss of ultrafi ltration capacity[J].Kidney International,1990,(03):495-506.
  • 4毛海萍,余学清.透析患者残存肾功能的临床重要性及保护策略[J].中华肾脏病杂志,2007,23(7):471-473. 被引量:11
  • 5Mortier S,Faict D,Lameire NH. Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model[J].Kidney International,2005,(04):1559-1565.doi:10.1111/j.1523-1755.2005.00237.x.
  • 6Medcalf JF,Walls J,Pawlaczyk IZ. Effects of glucose dialysateon extracellular matrix production by human peritoneal mesothelial cells(HPMC):The role of TGF beta[J].Nephrology Dialysis Transplantation,2001,(09):1885-1892.
  • 7Saglam F,Cavdar Z,Sarioglu S. Pioglitazone reduces peritoneal fibrosis via inhibition of TGF-β,MMP-2,and MMP-9 in a model of encapsulating peritoneal sclerosis[J].Renal Failure,2012,(01):95-102.
  • 8Hung KY,Chen CT,Huang JW. Dipyridamoleinhibits TGFbeta-induced collagen geneexpression in human peritonealmesothelial cells[J].Kidney International,2001,(04):1249-1257.doi:10.1046/j.1523-1755.2001.00933.x.
  • 9Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis:pathologic significance,molecular mechanism,and therapeutic intervention[J].Journal of the American Society of Nephrology,2004,(01):1-12.doi:10.1097/01.ASN.0000106015.29070.E7.
  • 10Franzén P,ten Dijke P,Ichijo H. Cloning of a TGF beta type Ⅰ receptor that forms a heteromeric complex with the TGF beta type Ⅱ receptor[J].Cell,1993,(04):681-692.

二级参考文献33

  • 1窦献蕊,余学清,王文健,郑智华,陈文芳,李晓艳,彭文兴,尹培达,贾占军,王欣,孙辽,张晖.一种新的大鼠慢性腹膜纤维化动物模型的建立[J].中华肾脏病杂志,2004,20(6):446-449. 被引量:18
  • 2郭志勇,袁伟杰,李保春,边琪,孙莉静,潘超,崔若兰.α-酮酸配伍低蛋白饮食对腹膜透析患者残余肾功能的保护作用[J].中国血液净化,2006,5(6):304-307. 被引量:7
  • 3Lin CY, Chen WP, Yang LY, et al.Persistent transforming growth factor-beta 1expression may predict peritoneal fibrosis in CAPD patients with frequent peritonitis occurrence. Am J Nephrol, 1998, 18:513-519.
  • 4Fracasso A, Baggio B, Ossi E, et al.Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis. Am J Kidney Dis, 1999, 33:105-110.
  • 5De Vriese AS, Flyvbjerg AF, Mortier S, et al. Inhibition of the interaction of AGE-RAGE prevents hyperglycemiainduced fibrosis of the peritoneal membrane. J Am Soc Nephrol, 2003, 14:2109-2118.
  • 6Margetts PJ, Kolb M, Galt T, et al. Gene transfer of transforming growth factor-betal to the rat peritoneam: effects on membrane function. J Am Soc Nephrol, 2001, 12:2029-2039.
  • 7Margetts PJ, Kolb M, Yu L, et al. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int, 2001, 21Suppl 3: S368-S372.
  • 8Biocompatibility of new peritoneal dialysis solutions. Proceedings of a seminar. Perit Dial Int, 2000,20 Suppl 5: S63-S68.
  • 9Henderson IS, Couper IA, Lumsden A.Potentially irritant glucose metabolites in unused CAPD fluids. In: Maher JFA,Winchester JF, eds. Frontiers in peritoneal Dialysis. New York: Field, Rich and Associates, 1986. 261-264.
  • 10Margetts PJ, Kolb M, Yu L, et al.Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol, 2002, 160: 2285-2294.

共引文献31

同被引文献130

引证文献10

二级引证文献51

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部